Fairvalue-Calculator Fairvalue-Calculator
EN DE

2cureX AB (2CUREX) Fair Value & Analysis

Healthcare · SE · Market cap 44.9M SEK

Pricekr 1.88
Fair Valuekr 0.9100
Upside-51.6%
Quality95/100
Evidence: Low Range kr 0.6900 – kr 1.14

Fair value as of: Jun 24, 2026

Analysis

2cureX AB (2CUREX) currently trades at kr 1.88, while our model-based Fair Value estimate is kr 0.9100 — implying the stock looks roughly 51.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is 2cureX AB (2CUREX) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 0.9100 versus a price of kr 1.88 — about −52% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 2CUREX?
Our 21-model fair value for 2cureX AB is kr 0.9100 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 1.88.
What is the quality score of 2CUREX?
2cureX AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.